Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06679881 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT06679881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
February 1, 2025
Completion date
December 31, 2028
Enrollment
170 (estimated)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)